VCAM1 and colorectal carcinoma: Although conventional anti-inflammatory therapeutics for IBD and CRC have traditionally been aimed at suppressing pleiotropic inflammatory mediators, the specific focal blockade of VCAM-1-mediated immune cell trafficking has gained considerable attention as a precise and effective strategy against colonic disease.